Investor Presentaiton
Sintilimab: Clinical Development Programs
4 indications approved, 1 sNDA under review in China, BLA accepted in US
INDICATION
China
r/r Classical Hodgkin's Lymphoma
1L Non-squamous NSCLC
1L Squamous NSCLC
1L Hepatocellular Carcinoma
2L Squamous NSCLC
EGFR+ TKI Failure NCSLC (MRCT)
1L Gastric Cancer
1L Gastric Cancer (CPS ≥10)
1L Esophageal Carcinoma (MRCT)
2L Classical Hodgkin's Lymphoma
Melanoma (adjuvant)
1L Hepatocellular Carcinoma
2L Hepatocellular Carcinoma
2L/+ Cervical cancer
2L ESCC
r/r NK/T-cell Lymphoma
3L CRC
Refractory Gastrointestinal Cancer
1L Gastric Cancer
MONO-/COMBO-THERAPY (OTHER COMPONENTS)
Mono
Combo (pemetrexed and cisplatin)
Combo (gemcitabine and platinum)
Combo (IBI-305/biosimilar to bevacizumab)
Mono
Combo (IBI-305/biosimilar to bavecizumab)
Combo (capecitabine and oxaliplatin)
Combo (Ramucizumab)
Combo (paclitaxel and cisplatin/5-FU and cisplatin)
Combo (ICE)
Combo (IBI-310/CTLA-4 mAb)
Combo (IBI-310/CTLA-4 mAb)
Combo (IBI-310/CTLA-4 mAb)
Combo (IBI-310/CTLA-4 mAb)
Mono
Mono
Combo (IBI-310/CTLA-4 mAb)
Mono
2L NSCLC
1L/2L Melanoma
Combo (capecitabine and oxaliplatin)
Mono
Mono
Combo (gemcitabine and cisplatin)
1L Squamous NSCLC
1L/2L Neuroendocrine Tumor
Solid Tumors/colorectal cancer
Solid Tumors/cholangiocarcinoma
3L colorectal cancer
2L Hepatocellular Carcinoma
U.S.
1L Non-squamous NSCLC
1L Esophageal Carcinoma (MRCT)
Solid Tumors
Combo (EP/IP)
Combo (Fruquintinib)
Combo (Surufatinib)
Combo (Chidamide)
Combo (siRNA)
Combo (pemetrexed and cisplatin)
Combo (paclitaxel and cisplatin/5-FU and cisplatin)
STATUS
1A
1B
PHASE 2
PHASE 3
NDA FILED
NDA APPROVED
Mono
Late Stage Endometrial Carcinoma
Mono
Symbols: = completed; = completed patient enrollment; ①= in progress;
= to be initiated within next quarter.View entire presentation